ADC Therapeutics (ADCT) Income from Continuing Operations (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Income from Continuing Operations of 32968000.0 for Q1 2026, up 14.6% year-on-year from 28769118.73 in Q1 2025, and up 19.52% on a QoQ basis from 40966000.0 in Q3 2025.
ADC Therapeutics (ADCT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Income from Continuing Operations for 7 consecutive years, with 32968000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 14.6% year-over-year to 32968000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 169182000.0 (down 3.0% YoY) and the FY2022 annual result came in at 152624000.0, up 33.84% from the prior year.
- Income from Continuing Operations grew to 32968000.0 in Q1 2026 per ADCT's latest filing, from 40966000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ADCT reached as high as 16661000.0 in Q1 2022 and fell as low as 64374000.0 in Q2 2022.
- A 5-year average of 42683000.0 and a median of 44505500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 67.67% — and 2023, when it sank 256.68%.
- Year by year, Income from Continuing Operations stood at 18153000.0 in 2022, then slumped by 149.56% to 45302000.0 in 2023, then climbed by 3.52% to 43709000.0 in 2024, then increased by 6.28% to 40966000.0 in 2025, then climbed by 19.52% to 32968000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 32968000.0, 40966000.0, and 56646000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | -32.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -56.65 Mn |
| Mar 31, 2025 | -38.60 Mn |
| Sep 30, 2024 | -43.71 Mn |
| Jun 30, 2024 | -35.95 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Sep 30, 2023 | -45.30 Mn |
| Jun 30, 2023 | -48.20 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -50.61 Mn |
| Jun 30, 2022 | -64.37 Mn |
| Mar 31, 2022 | -16.66 Mn |
| Dec 31, 2021 | -35.52 Mn |
| Sep 30, 2021 | -71.55 Mn |
| Jun 30, 2021 | -72.57 Mn |
| Mar 31, 2021 | -51.53 Mn |
| Dec 31, 2020 | -56.26 Mn |
| Sep 30, 2020 | -20.33 Mn |